Will Health Care Reform Stifle Pharma Innovation?

New health care laws will have unintended consequences that may hold the drug industry back, particularly in regards to biosimilars. The new biosimilar legislation is "an important first step," says Deloitte's Matthew Hudes, but there is much work to do, with FDA the key player.